### Highlights of This Issue

#### SPECIAL FEATURES

**CCR Translations**
- **Molecular Targeting of Neural Cancer Stem Cells: TTAGGG, Youre It!**
  Anita B. Hjelmeland and Jeremy N. Rich
  See article p. 111

**CCR New Strategies**
- **New Strategies in the Molecular Targeting of Glioblastoma: How Do You Hit a Moving Target?**
  Timothy F. Cloughesy and Paul S. Mischel

**Molecular Pathways**
- **p27: A Barometer of Signaling Deregulation and Potential Predictor of Response to Targeted Therapies**
  Seth A. Wander, Dekuang Zhao, and Joyce M. Slingerland

**Review**
- **Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies**
  Guillaume Cartron, Ralf Ulrich Trappe, Philippe Solal-Celigny, and Michael Hallek

### HUMAN CANCER BIOLOGY

**Frequent hSNF5/INI1 Germline Mutations in Patients with Rhabdoid Tumor**
Franck Bourdeaut, Delphine Lequin, Laurence Brugères, Stéphanie Reynaud, Christelle Dufour, François Doz, Nicolas André, Jean-Louis Stephan, Yves Pérel, Odile Oberlin, Daniel Orbach, Christophe Bergeron, Xavier Rialland, Paul Fréneaux, Dominique Ranchere, Dominique Figarella-Branger, Georges Audry, Stéphanie Puget, D. Gareth Evans, Joan Carles Ferreres Pinas, Valeria Capra, Véronique Mosseri, Isabelle Coupier, Marion Gautier-Villars, Gaelle Pierron, and Olivier Delattre

**Long Exposure of Environmental Tobacco Smoke Associated with Activating EGFR Mutations in Never-Smokers with Non–Small Cell Lung Cancer**
Tomoya Kawaguchi, Masahiko Ando, Akihito Kubo, Minoru Takada, Shinji Atagi, Kyoichi Okishio, Kazuhiro Asami, Akihide Matsumura, Kazunyu Tsujino, Sai-Hong Ignatius Ou, and Hidefumi Sasaki

**Characterization of Tumor-Suppressive Function of SOX6 in Human Esophageal Squamous Cell Carcinoma**
Yan-Ru Qin, Hong Tang, Fajun Xie, Haibo Liu, Yinghui Zhu, Jiaoyu Ai, Leilei Chen, Yan Li, Dora L. Kwong, Li Fu, and Xin-Yuan Guan

**Ewing Tumors That Do Not Overexpress BMI-1 Are a Distinct Molecular Subclass with Variant Biology: A Report from the Children’s Oncology Group**
Aaron Cooper, John van Doorninck, Lingyun Ji, Darren Russell, Marc Ladanyi, Hiroyuki Shimada, Mark Kralio, Richard B. Womer, Jessie Hao-ru Hsu, Dafydd Thomas, Timothy J. Triche, Richard Sposto, and Elizabeth R. Lawlor
CANCER THERAPY: PRECLINICAL

67 Polysaccharide Krestin Is a Novel TLR2 Agonist that Mediates Inhibition of Tumor Growth via Stimulation of CD8 T Cells and NK Cells
Hailing Lu, Yi Yang, Ekram Gadi, Cynthia A. Wenner, Amy Chang, Emily R. Larson, Yushe Dang, Mark Martzen, Leanna J. Standish, and Mary L. Disis

77 Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow Transplantation
Isao Tawara, Motoko Koyama, Chen Liu, Tomomi Toubai, Dafydd Thomas, Rebecca Evers, Peter Chockley, Evelyn Nieves, Yaping Sun, Kathleen P. Lowler, Chelsea Malter, Norhiro Nishimoto, Geoffrey R. Hill, and Pavan Reddy

89 Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation
Mohamed A. Elmeliegy, Angel M. Carcaboso, Michael Tagen, Feng Bai, and Clinton F. Stewart

100 A Novel Fusion Toxin Derived from an EpCAM-Specific Designed Ankyrin Repeat Protein Has Potent Antitumor Activity
Patricia Martin-Killias, Nikolas Stefan, Sacha Rothschild, Andreas Pluckthun, and Uwe Zangemeister-Wittke

111 Neural Tumor-Initiating Cells Have Distinct Telomere Maintenance and Can be Safely Targeted for Telomerase Inhibition
Pedro Castelo-Branco, Cindy Zhang, Tatiana Lipman, Mayumi Fujitani, Loen Hansford, Ian Clarke, Calvin B. Harley, Robert Tressler, David Malkin, Erin Walker, David R. Kaplan, Peter Dirks, and Uri Tabori
See commentary p. 3

122 Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET-Amplified Tumor Cells with or without Resistance to Selective MET Inhibition
Thomas Bachleitner-Hofmann, Mark Y. Sun, Chin-Tung Chen, David Liska, Zhaozhi Zeng, Agnes Viale, Adam B. Olshen, Martina Miltlböck, James G. Christensen,Neal Rosen, David B. Solit, and Martin R. Weiser

CANCER THERAPY: CLINICAL

134 The Ability to Form Primary Tumor Xenografts Is Predictive of Increased Risk of Disease Recurrence in Early-Stage Non–Small Cell Lung Cancer
Thomas John, Derek Kohler, Melanie Pintillie, Naoki Yanagawa, Nhu-An Pham, Ming Li, Devang Panchal, Frances Hui, Fannong Meng, Frances A. Shepherd, and Ming-Sound Tsao

142 Pazopanib Reveals a Role for Tumor Cell B-Raf in the Prevention of HER2+ Breast Cancer Brain Metastasis
Brunilde Grill, Diane Palmieri, Yong Qian, DeeDee Smart, Lilia Ileva, David J. Liewehr, Seth M. Steinberg, and Patricia S. Steeg

IMAGING, DIAGNOSIS, PROGNOSIS

154 Combined Analysis of Estrogen Receptor β-1 and Progesterone Receptor Expression Identifies Lung Cancer Patients with Poor Outcome
Laura P. Stabile, Sanja Dacic, Stephanie R. Land, Diana E. Lenzner, Rajiv Dhir, Marie Acquafondata, Rodney J. Landreneau, Jennifer R. Grandis, and Jill M. Siegfried

165 Prognostic Significance of the Detection of Peripheral Blood CEACAM5mRNA-Positive Cells by Real-Time Polymerase Chain Reaction in Operable Colorectal Cancer
Nikolaos Vardakis, Ippokratis Messaritakis, Chara Papadaki, Georgios Agoglossakis, Maria Sfakiakaki, Zachareia Saridaki, Stella Apostolaki, Ioannis Koutroubakis, Maria Perraki, Dora Hatziidak, Dimitris Mavroudis, Vassilis Georgoulias, and John Souglakos

174 Total Marrow Irradiation: A New Ablative Regimen as Part of Tandem Autologous Stem Cell Transplantation for Patients with Multiple Myeloma
George Somlo, Ricardo Spielberger, Paul Frankel, Chatchada Karanes, Amrita Krishnan, Pablo Parker, Leslie Popplewell, Firoozeh Sahebi, Neil Kogut, David Snyder, An Liu, Timothy Schulteiss, Stephen Forman, and Jeffrey Y. C. Wong

American Association for Cancer Research
| 183 | **Phase I Trial of TGF-β2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine**  
Jairo Olivares, Padmasini Kumar, Yang Yu, Phillip B. Maples, Neil Senzer, Cynthia Bedell, Minal Barve, Alex Tong, Beena O. Pappen, Joseph Kuhn, Mitchell Magee, Gladice Wallraven, and John Nemunaitis |
|---|---|
| 193 | **Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies**  
Monica Mita, Kevin R. Kelly, Alain Mita, Alejandro D. Ricart, Ofelia Romero, Anthony Tolcher, Laurel Hook, Chukwuemeka Okereke, Ilya Krivelevich, Daniel P. Rossignol, Francis J. Giles, Eric K. Rowinsky, and Chris Takimoto |

**ABOUT THE COVER**

Human glioma tumor initiating cells are targets for telomerase inhibition. Immunofluorescence studies show that glioma tumor-initiating cells express high levels of nestin (neuronal precursor cells marker, shown in green). These cells have substantially higher telomerase activity than normal tissue stem cells and can therefore be specifically and safely targeted for telomerase inhibition. For further details, please see Castelo-Branco and coworkers on page 111 in this issue.